Phreesia Stock Fair Value Calculator – “Analysts Agree: PHREESIA Gets a “Moderate Buy” Rating
January 30, 2023
Trending News ☀️
Phreesia Stock Fair Value Calculator – Analysts have recently assigned a consensus rating of “Moderate Buy” to PHREESIA ($NYSE:PHR), a leading provider of cloud-based patient intake and payment solutions for the healthcare industry. This is great news for investors, as it indicates that PHREESIA is a reliable and worthwhile investment. The company’s products are designed to help healthcare organizations streamline their patient intake and payment processes and reduce administrative costs. PHREESIA’s services include patient check-in, eligibility verification, appointment scheduling, co-pay collection, and patient engagement tools. The “Moderate Buy” rating assigned to PHREESIA by analysts is an indication that the stock is worth investing in. Analysts believe that the company’s innovative technology and strong customer base will help it continue to grow and generate returns for investors over the long term.
Analysts also note that PHREESIA has experienced strong revenue growth in recent years, which is a positive sign that its products are in demand. The company has also seen an increase in customer retention rates, as its products are used by more healthcare organizations each year. Overall, analysts believe that PHREESIA is an attractive investment opportunity. As such, they recommend that investors consider adding it to their portfolios. With its innovative technology and strong customer base, PHREESIA is well-positioned to continue to grow and generate returns for investors in the years ahead.
Market Price
Analysts agree that PHREESIA warrants a “moderate buy” rating. As of the time of writing, news about the company is mostly positive. This is reflected in its stock price; on Wednesday, PHREESIA opened at $34.3 and closed at $35.0, representing an increase of 1.0% from its previous closing price of $34.6. This is not the first time PHREESIA has been rated favorably by analysts. In fact, the company has consistently been rated as a “moderate buy” for the past few months. This suggests that investors have a positive outlook on the company and believe it will continue to perform well in the future. The company’s strong performance is likely due to its innovative technology and focus on customer satisfaction. PHREESIA has developed a platform that streamlines the registration process for healthcare providers and their patients. This platform makes it easier for providers to collect and keep track of patient data, allowing them to provide better care.
Additionally, PHREESIA has consistently focused on improving its customer service, which has led to an increase in customer loyalty. The company’s strong performance and innovative technology have made it a desirable stock for investors. Going forward, investors should continue to monitor PHREESIA’s progress and maintain a positive outlook on the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Phreesia. More…
| Total Revenues | Net Income | Net Margin |
| 262.34 | -184.58 | -70.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Phreesia. More…
| Operations | Investing | Financing |
| -112.2 | -60.27 | -18.33 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Phreesia. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 397.29 | 76.95 | 6.08 |
Key Ratios Snapshot
Some of the financial key ratios for Phreesia are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 30.4% | – | -69.7% |
| FCF Margin | ROE | ROA |
| -52.6% | -34.2% | -28.8% |
VI Analysis – Phreesia Stock Fair Value Calculator
The VI app has made it easy to analyze the company’s fundamentals simply and quickly. According to the VI Line, the fair value of PHREESIA‘s share is around $51.1. Currently, the stock is trading at $35.0, which is 32% lower than the fair value. This suggests that PHREESIA stock is currently undervalued and potential investors may take advantage of this opportunity. Investors should also consider other factors, such as the company’s growth prospects, competitive position, financial stability and management team, before making a decision. It is important to note that past performance does not guarantee future results and that investing in stocks carries risk. Therefore, it is essential to do adequate research and make an informed decision before investing in the stock. More…
VI Peers
Its competitors include Sharecare Inc, Aclarion Inc, and Cloud DX Inc.
– Sharecare Inc ($NASDAQ:SHCR)
Sharecare is a digital health company that allows users to manage their health and wellness in one place. The company has a wide range of products and services, including a social media platform, a health information database, and a mobile app. The company also offers a variety of health and wellness products and services, including fitness tracking, nutrition counseling, and stress management.
– Aclarion Inc ($NASDAQ:ACON)
Aclarion Inc is a publicly traded company with a market cap of 6.36M as of 2022. The company has a Return on Equity of -186.66%. Aclarion is a provider of cloud-based software solutions for the management of enterprise content. The company’s products and services include content management, document management, records management, and compliance management. Aclarion’s solutions are used by organizations in a variety of industries, including healthcare, financial services, government, and education.
– Cloud DX Inc ($TSXV:CDX)
A market cap is the total value of all a company’s shares of stock. Market cap is calculated by multiplying a company’s shares outstanding by the current market price of one share. The return on equity is a financial ratio that measures the profitability of a company in relation to the equity. The company’s equity is the difference between its total assets and total liabilities. The company’s ROE is its net income divided by its equity.
The company’s market cap is 10.81M as of 2022. The company’s ROE is 111.76%. The company’s net income is its total assets minus its total liabilities. The company’s market cap is its shares outstanding multiplied by the current market price of one share.
Summary
Investment analysts have given PHREESIA a moderate “Buy” rating, indicating that the company’s stock has medium-term growth potential. At the time of writing, news about the company is generally positive. The company is a provider of digital patient intake and engagement solutions for the healthcare industry. PHREESIA offers a comprehensive suite of software, hardware, and services to help streamline patient registration, automate payments, and enhance the patient experience.
Its analytics capabilities allow healthcare organizations to better understand their patient populations and make informed decisions about their operations. Investment in PHREESIA can provide medium-term growth opportunities for investors looking to benefit from the company’s position as a leader in healthcare technology.
